Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 09, 2024 09:00 ET | Source: Muscular Dystrophy Association

MDA Kickstart Program Launches for Ultra-Rare Neuromuscular Disease Drug Development

New York, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA) announced today a new research program called MDA Kickstart for Ultra-Rare Neuromuscular Disease. The MDA...
August 05, 2024 12:28 ET | Source: Osteal Therapeutics

Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting

DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
July 24, 2024 08:05 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Enters Into an Exclusive License, Supply and Commercialization Agreement with Kye Pharmaceuticals for AGAMREE® in Canada

CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing,...
July 16, 2024 09:00 ET | Source: Flag Therapeutics, Inc.

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)

FLAG Therapeutics Announces Encouraging Preclinical Data from Studies of FLAG-003 for the Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)
July 16, 2024 08:37 ET | Source: Trethera Corporation

Trethera Receives $2M NIH Grant for Preclinical Development in the Pediatric Neurologic Disease Acute Disseminated Encephalomyelitis

LOS ANGELES, July 16, 2024 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
July 02, 2024 04:01 ET | Source: Research and Markets

Rare Diseases Global Market Report 2024-2034: Robust Pipeline by Major Players and Increasing Number of Drug Approvals

Dublin, July 02, 2024 (GLOBE NEWSWIRE) -- The "Rare Diseases Market Report 2024-2034" has been added to ResearchAndMarkets.com's offering.World revenue for the Rare Diseases Market is forecast to...
June 28, 2024 10:26 ET | Source: Research and Markets

Registrations Open for the 2024 Orphan Drugs and Rare Diseases Conference - Boston, MA, United States - October 17-18th, 2024

Dublin, June 28, 2024 (GLOBE NEWSWIRE) -- The "Orphan Drugs and Rare Diseases" conference has been added to ResearchAndMarkets.com's offering. The 2 day Orphan Drugs and Rare Diseases Conference...
June 21, 2024 09:15 ET | Source: Research and Markets

Global $38.9 Billion Medical Food Market by Category, Type, Form, Distribution Channel, Application, and Region - Forecast to 2030

Dublin, June 21, 2024 (GLOBE NEWSWIRE) -- The "Global Medical Food Market 2024-2030" report has been added to ResearchAndMarkets.com's offering.The Medical Food Market size was estimated at USD...
June 11, 2024 07:59 ET | Source: Sixty Degrees Pharmaceuticals

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

60 Degrees Pharmaceuticals receives FDA orphan drug status for tafenoquine to treat acute babesiosis, offering market exclusivity and tax incentives.
June 05, 2024 09:00 ET | Source: Osteal Therapeutics

Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate

Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.